Brief History of Novel Pandemic Influenza A H1N1 {#Sec00151}
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The first cases of the novel influenza A(H1N1) virus were reported in April 2009, especially in Mexico and the United States \[[@CR00151], [@CR00152]\]. The disease spread rapidly, becoming a pandemic by June 2009. On August 21, 2009, a total of 177 reported cases of novel influenza 182.166 A(H1N1) infection, of which 1,799 were fatal \[[@CR00152]\]. It has been observed in animal studies that the novel influenza virus A has a high replication rate in lung tissue, with a great capacity to invade the lower respiratory tract in humans, causing especially acute fulminant respiratory failure.

The acute respiratory failure (ARF) in patients with novel H1N1 disease---its most severe form of presentation---includes diffuse pulmonary infiltrates and severely compromised oxygenation. The alveolar-arterial gradient of oxygen is also compromised once the acute respiratory syndrome (ARDS) is established.

Studies on the management of patients with ARF and infection with novel H1N1 influenza are based on the most severe form of respiratory failure, multiple pulmonary infiltrates, PaO~2~/FiO~2~ \> 200, and even severe multiple organ damage.

Novel H1N1 influenza infection is a disease whose lethality is based on the presence of progressive ARF for 48--72 h after presentation of the disease. Hence, there is a period during which the disease is becoming established and therefore when early intervention could halt its progression, thereby reducing its morbidity and mortality.

Ventilatory Strategies to Combat Acute Respiratory Failure (Nonhypoxemic Patients) {#Sec00152}
==================================================================================

Although the lethal form is the appearance of refractory hypoxemic ARF infection, novel influenza A(H1N1) can present as ARF due to exacerbation of a chronic respiratory lung disease \[e.g., asthma, chronic obstructive pulmonary disease (COPD)\], other chronic respiratory diseases, bacterial pneumonia secondary to infection with novel influenza A(H1N1), or viral pneumonitis \[[@CR00153]\].

The European Respiratory Society (ERS) and the European Society of Intensive Care Medicine (ESICM) stated that noninvasive mechanical ventilation (NIMV) \[[@CR00154]\] should not be considered a treatment for hypoxemic ARF secondary to a pandemic and likely to progress to ARDS. The main reasons NIMV should not be considered the first line of treatment are the following: (1) It has poor clinical efficacy regarding severe ARF that rapidly progresses to ARDS. (2) Patients infected with the novel influenza A(H1N1) virus have more heterogeneous hypoxemic ARF than patients with hypercapnic respiratory failure. (3) Aerosol particles released by NIMV expand and spread the infection.

The use of NIMV can be justified, however, to avoid endotracheal intubation in certain cases. The types of the ARF for which NIMV can be prescribed are in patients who are experiencing exacerbation of chronic respiratory lung diseases, such as asthma or COPD, and other chronic respiratory disease, bacterial pneumonia secondary to infection with novel influenza A(H1N1), and mild viral pneumonitis (PaO~2~/FiO~2~ \> 200).

Hajjar et al. \[[@CR00155]\] treated five patients (62.5 %) who required invasive mechanical ventilation during the first 24 h after ICU admission. NIMV was useful in three of the patients (37.5 %), each of whom had a mild form of the disease assessed by computed tomography. Estenssoro et al. \[[@CR00156]\] used NIMV in 64 patients (19 %) with good results in patients with mild to moderate disease.

Briones Claudett et al. \[[@CR00157]\] reported two patients who required noninvasive ventilation (NIV) with favorable results. NIMV was initiated using bilevel positive airway pressure (BIPAP) mode S/T (spontaneous/timed) with a respiratory rate of 15. It had a programmed tidal volume (Vt) of 200 ml exhaled for a 42-kg patient and 300 ml for a 60-kg patient, each infected with influenza A novel associated H1N1 and chronic lung disease. The average volume-assured pressure support (AVAPS) ventilatory strategy was useful in patients with COPD exacerbation, infection, asthma, and those with mild forms of novel influenza A(H1N1) infection. The S/T-BIPAP + AVAPS ventilation strategy allows a fixed preset tidal volume that is maintained constant under inspiratory pressure variations. (BiPAP S/T) with average volume assured pressure support (AVAPS) allows for setting a fixed tidal volume, and the system output automatically adjusts based on variations in inspiratory pressure to ensure the predetermined target value. The initial ventilatory parameters must be programmed in mode BIPAP-S/T + AVAPS with an inspiratory pressure (IPAP) of 18--26 cmH~2~O and a minimum of 12 applications scheduled as well as positive expiratory pressure (EPAP) of 6--8 cmH~2~O for a programmed tidal volume corresponding to 45.5 + 0.91 (height in cmt -- 152.4). 8--10 ml/kg body weight per patient. Were given supplements O~2~ via an adapter circuit close to the facemask in order to maintain SaO~2~ above 94 % (Fig. [15.1](#Fig1){ref-type="fig"}).Fig. 15.1Ventilatory strategy with BiPAP S/T and average volume assured pressure support (AVAPS)

Noninvasive Ventilation Strategies in Hypoxemic Patients {#Sec00153}
========================================================

The Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) drew up recommendations regarding the use of NIV during the pandemic that followed the 2010--2011 epidemic. It stated that it is not advisable to use noninvasive ventilation in patients who require respiratory support where there is high suspicion of infection with the new influenza virus A(H1N1) \[[@CR00158]\]. The reason for this recommendation is the risk of its generating aerosols, which increase the risk of transmission to health care workers. Also, it usually contributes to a poor clinical outcome in these patients. Before deciding to use NIMV, the risk-benefit ratio should be assessed, especially considering certain aspects, shown in Table [15.1](#Tab00151){ref-type="table"}.Table 15.1Use of noninvasive mechanical ventilation in the presence of influenza virus A(H1N1) infection(a) Reserve noninvasive mechanical ventilation (NIMV) for patients with acute respiratory distress syndrome without severe criteria.(b) Perform NIMV preferably in negative-pressure rooms.(c) Preferably use respirators with dual circuits.(d) Use accessory airways safely (e.g., masks that cover the entire face).(e) Practice strict compliance with all security measures for staff (air insulation).(f) Never undertake invasive mechanical ventilation in the emergency room or shared rooms.

The ERS/ESICM recommend avoiding NIMV. Instead, they recommend intubating patients infected with the new H1N1 virus who have been admitted to an intensive care unit (ICU) with severe hypoxemia that rapidly develops into ARDS, multiple organ failure, and refractory hypoxemia. NIMV should be considered only for patients with moderate hypercapnic ARF secondary to exacerbation of a chronic respiratory disorder, ARF secondary to acute pulmonary edema, or ARF after extubation secondary to ARDS due to H1N1 virus infection. (Fig. [15.2](#Fig2){ref-type="fig"}).Fig. 15.2"Open lung" management of ARDS

There are some reports in the literature of using NIMV in patients with novel influenza A(H1N1) infection. Winck and Marinho \[[@CR00159]\] described a 53-year-old patient who underwent NIV (BiPAP Vision; Philips Respironics, Murrysville, PA, USA) with an orofacial mask in a bilevel mode with inspiratory pressure (IPAP) of 16 cmH~2~O and expiratory pressure in the airway (EPAP) of 8 cmH~2~O that was initiated and then switched to continuous positive pressure airway (CPAP) of 10 cmH~2~O with FiO~2~ at 25 %. After 1 h, the PaO~2~/FiO~2~ increased to 364, and CPAP was discontinued 12 h later.

Djibré et al. \[[@CR001510]\] reported a case of a 38-year-old woman at 31 weeks' gestation who underwent continuous NIMV for 72 h through a face mask with an FiO~2~ of 100 %, IPAP of 14 cmH~2~O, and EPAP of 5 cmH~2~O.

Rello et al. \[[@CR00153]\] reported that after 3 days of intermittent NIMV 6 (75 %) of the 8 (33.3 %) patients who underwent NIMV required intubation and IMV. Two of them (33 %) died anyway. The SOFA score at hospital admission in the patients who failed NIMV (8.1 ± 2.3) was higher than that in those who responded to the NIMV (2.5 ± 0.7) (*p* = 0.01).

Miller et al. \[[@CR0015103]\] reported 13 patients on NIMV, but 11 of them were intubated within a median of 7.9 (IQR 2.8--20.8) hours. Krumar et al. \[[@CR001511]\] reported 136 patients (81.0 %) who were mechanically ventilated the first day of ICU admission. Among them, 128 (76.2 %) underwent IMV and 55 (32.7 %) NIMV. In all, 47 of the NIMV patients (85.4 %) were switched to IMV. There was another report of a small number of patients, with 5 of the 10 patients having pneumonia and hypoxemic failure. NIMV was 100 % effective in terms of improving oxygenation and avoiding intubation. It should be noted, however, that these patients had only respiratory failure when starting the NIMV, with no other organs compromised \[[@CR001522]\].

For patients who present with severe disease, it is prudent to perform early intubation and/or admission to the ICU given the rapid progression in these cases. NIMV has little success here. During the pandemic it was reported that NIMV was used in 25--45 % of patients, with a 75 % failure rate \[[@CR00153], [@CR001511], [@CR001512]\].

In the Canadian experience, approximately 30 % of patients were admitted to the ICU and underwent NIMV. Altogether, 85 % of them required subsequent intubation and invasive ventilation. Given the high failure rate and duration of ventilatory support, routine use of NIMV in patients with H1N1 should be avoided. The reasons for failure of NIMV in this population may be that the patients almost uniformly present with hypoxemic respiratory failure and normal PaCO~2~. Furthermore, improvement and resolution of H1N1 pneumonitis is generally slow, so NIVM may be less useful.

Patients' ventilation should be managed with a protective strategy: low tidal volumes (target 6 ml/kg) \[[@CR001514]\], opening strategy lung ventilation with PEEP adjusted based on the FiO~2~ to a plateau pressure of 30--35 cmH~2~O and SpO~2~ of 88--90 % (ARDS Network protocol) \[[@CR001523]\]. Amato \[[@CR001513]\] showed how using lower tidal volume and higher PEEP reduced mortality by 33 % (NNT = 3). The ARIES study NETWORK of Jesus Villar et al. \[[@CR001514]\] reported similar results.

Three studies addressed the use of high levels of PEEP with low tidal volume: EXPRESS, LOVs, and ALVEOLI \[[@CR001515]--[@CR001517]\]. In the LOVS study, the authors compared 10 vs. 16 cmH~2~O of PEEP in patients who had low tidal volume. Amato et al.'s patient group was employed as the controls. The EXPRESS study employed the ARDS Network protocol control group and compared PEEP levels of 7 vs. 15 cmH~2~O. Mortality was similar in the three studies. In the ALVEOLI study clinical outcomes were similar whether lower or higher PEEP levels were used. A recent meta-analysis \[[@CR001518]\] examined three trials involving 2,299 patients and demonstrated that high PEEP levels was not associated with improved hospital survival. This protective ventilatory strategy has traditionally been associated with reduced mortality. It should be noted, however, that several recent meta-analyses of randomized trials using ventilatory strategies to protect the tidal volume in the lungs demonstrated that it is not the most important parameter. They concluded that the driving pressure is the difference between the plateau pressure and PEEP during controlled ventilation, which is therefore the most important parameter to optimize \[[@CR001519]\].

Amato et al. demonstrated reduced mortality using recruitment maneuvers (CPAP 40 cmH~2~O). Borges et al. \[[@CR001520]\] used a technique aimed at achieving 95 % lung recruitment. Its success was confirmed by blood gas tomographic studies. The aim of recruitment maneuvers is to achieve and maintain effective lung reexpansion over time by selecting an appropriate level of PEEP.

A prospective cohort study in Ecuador included 24 ARDS patients. It was highly suspected that the ARDS was caused by influenza A(H1N1) \[[@CR001521]\]. The patients had a mean PaO~2~/FiO~2~ of 112 ± 34 and a mean APACHE II score of 18.83 ± 5.1. The patients were treated using maximizing recruitment maneuvers. The reported ICU mortality was 16.6 %.

Alternative modes of ventilation---placing the patient in a prone position or applying high-frequency oscillatory ventilation, release airway pressure ventilation (APRV), or high-frequency ventilation (HFV)---may improve oxygenation in intubated patients. APRV is a time-triggered, pressure-cycled ventilation mode that allows spontaneous breaths throughout the respiratory cycle. It has been widely used in patients with ARDS and has been observed to improve oxygenation. It also reduces the need for sedation and paralysis. During APRV, pressure in the airway is scheduled on two levels called P~high~ and P~low~ and into two periods called T~high~ and T~low~. They are analogous to inspiratory pressure, PEEP, inspiratory time, and expiratory time, respectively. There are no conclusive data pertaining to whether APRV improves or worsens the results in patients with lung injury, particularly because the combination of pressure and the controlled mode can produce unpredictable spontaneous breaths and tidal volumes. It is known that high tidal volumes are associated with worse ARDS outcomes \[[@CR001523]\].

Sundar et al. \[[@CR001524]\] found that 11 of 14 patients had refractory hypoxemia despite APRV application. However, by combining the use of APRV with placing the patient in a prone position reduced mortality by 27.3 % (3/11). The authors concluded that the prone position combined with APRV improves oxygenation and limits organ dysfunction in patients with ARDS due to novel influenza A(H1N1).

The Spanish Working Group on Influenza A (SEMICYUC) noted that 75--90 % of patients who require mechanical ventilation and had severe hypoxemia require rescue treatment how: inhaled nitric oxide, high-frequency ventilation, or membrane oxygenation by extracorporeal circulation.

Administration of inhaled nitric oxide, high-frequency ventilation, or membrane oxygenation by extracorporeal circulation \[[@CR001525], [@CR001526]\] are still controversial.

Conclusion {#Sec00154}
==========

Various techniques can be used clinically in strategies to address ARF due to novel influenza infection A(H1N1). NIMV should be reserved for special cases. The risk-benefit ratio regarding use of NIMV should be carefully evaluated. NIMV should not be used in patients with moderate to severe ARDS. Ventilation strategies using both noninvasive strategies (BIPAP S/T or BiPAP S/T + AVAPS) and invasive strategies (protective ventilation strategy with recruitment maneuvers, APRV) have proven useful in various clinical scenarios.
